Efficacy and safety of anlotinib in overall and disease-specific advanced gynecological cancer: A real-world study.

• DOI: 10.1200/jco.2023.41.16_suppl.5608
• Publication Date: 2023-06-04T15:54:08Z
• Authors: Xinyi Hong; Shanhu Qiu; Xia Wu; Sizhen Chen; Xiaoxiang Chen; Bei Zhang; Aiqin He; Ying Zhou; Yun Xu; Jianqing Wang; Yingchun Gao; Xizhong Xu; Li Sun; Yang Zhang; Libing Xiang; Jundong Zhou; Qun Guan; Bingwei Chen; Yang Shen

5608 Background: Anlotinib is a novel oral small-molecule multi-target tyrosine kinase inhibitor that has been approved for treating non-small cell lung cancer. However, its efficacy and safety among patients with advanced gynecological We conducted this study to address issue in the real-world setting. Methods: Data from treated anlotinib persistent, recurrent or metastatic cancer including cervical, endometrial, ovarian were collected 17 centers August 2018. The database lock-time was on March 2022. administered orally days 1–14 every 3 weeks until disease progression, severe toxicity occurred, death. outcomes included objective response rate (ORR), control (DCR), progression-free survival (PFS). Results: A total of 249 analyzed, median follow-up 14.46 months. overall ORR DCR 28.1% (95% CI 22.6% 34.1%), 80.7% 75.3% 85.4%), respectively. Specifically, varied 19.7% 34.4% differed 81.7% 90.0% disease-specific PFS 6.1 months ranged 5.6 10.0 cancer, Larger cumulative dosage (>700 mg) general associated longer most common adverse event related use pain/arthralgia (18.3%). Conclusions: In conclusion, holds promise such as reasonable tolerable safety.